CN114949139A - 一种缓解酒精性肝损伤的组合物及其制备工艺 - Google Patents
一种缓解酒精性肝损伤的组合物及其制备工艺 Download PDFInfo
- Publication number
- CN114949139A CN114949139A CN202210536391.3A CN202210536391A CN114949139A CN 114949139 A CN114949139 A CN 114949139A CN 202210536391 A CN202210536391 A CN 202210536391A CN 114949139 A CN114949139 A CN 114949139A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- composition
- liver injury
- alcoholic liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 54
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 54
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 146
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 64
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 35
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 29
- 239000000600 sorbitol Substances 0.000 claims abstract description 29
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 28
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 28
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 26
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 25
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 25
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 25
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 25
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 24
- 235000013976 turmeric Nutrition 0.000 claims abstract description 24
- 240000001548 Camellia japonica Species 0.000 claims abstract description 22
- 235000018597 common camellia Nutrition 0.000 claims abstract description 22
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 claims abstract description 21
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 21
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003767 alanine Drugs 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000811 xylitol Substances 0.000 claims abstract description 21
- 235000010447 xylitol Nutrition 0.000 claims abstract description 21
- 229960002675 xylitol Drugs 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 21
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract description 20
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 20
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 20
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims description 37
- 240000008790 Musa x paradisiaca Species 0.000 claims description 34
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 34
- 238000001035 drying Methods 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 25
- 229920002472 Starch Polymers 0.000 claims description 24
- 239000008107 starch Substances 0.000 claims description 24
- 244000111489 Gardenia augusta Species 0.000 claims description 23
- 239000013067 intermediate product Substances 0.000 claims description 23
- 238000007873 sieving Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 229920000294 Resistant starch Polymers 0.000 claims description 16
- 238000012856 packing Methods 0.000 claims description 16
- 235000021254 resistant starch Nutrition 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000002244 precipitate Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108090000637 alpha-Amylases Proteins 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000007974 sodium acetate buffer Substances 0.000 claims description 5
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims 4
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 235000020985 whole grains Nutrition 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 16
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 10
- 210000000952 spleen Anatomy 0.000 abstract description 10
- 210000002784 stomach Anatomy 0.000 abstract description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 8
- 238000007254 oxidation reaction Methods 0.000 abstract description 8
- 208000007848 Alcoholism Diseases 0.000 abstract description 7
- 230000003647 oxidation Effects 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 201000007930 alcohol dependence Diseases 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 239000003440 toxic substance Substances 0.000 abstract description 5
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 abstract description 4
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 230000004438 eyesight Effects 0.000 abstract description 4
- 231100000167 toxic agent Toxicity 0.000 abstract description 4
- 230000003750 conditioning effect Effects 0.000 abstract description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 2
- 229930006000 Sucrose Natural products 0.000 abstract description 2
- 240000001972 Gardenia jasminoides Species 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 25
- 241000245665 Taraxacum Species 0.000 description 24
- 235000019441 ethanol Nutrition 0.000 description 24
- 235000009508 confectionery Nutrition 0.000 description 16
- 238000005469 granulation Methods 0.000 description 14
- 230000003179 granulation Effects 0.000 description 14
- 238000005303 weighing Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000002274 desiccant Substances 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 239000002932 luster Substances 0.000 description 7
- 239000005022 packaging material Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000002633 protecting effect Effects 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 238000005054 agglomeration Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229960002920 sorbitol Drugs 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 235000018958 Gardenia augusta Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- -1 oxygen free radical Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001328788 Camellia nitidissima Species 0.000 description 1
- 241001657422 Camellia petelotii Species 0.000 description 1
- 101100081581 Chlamydomonas reinhardtii ODA1 gene Proteins 0.000 description 1
- 101100224940 Chlamydomonas reinhardtii ODA2 gene Proteins 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000731396 Pueraria montana var. thomsonii Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241001062811 Stewartia malacodendron Species 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种缓解酒精性肝损伤的组合物及其制备工艺,本发明制备的缓解酒精性肝损伤的组合物主要包括如下组分:枳椇子粉、葛根粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶、L‑丙氨酸、L‑谷氨酰胺、山梨糖醇、异麦芽酮糖醇、木糖醇、硬脂酸镁。本发明制备的缓解酒精性肝损伤的组合物成分天然,口感良好,不添加蔗糖,能有效减缓乙醇氧化成有毒物质乙醛,降低乙醛对身体的损害,具备清热解毒、清肝明目、调理肾脏及脾胃,加速酒毒的分解与排泻的功效。
Description
技术领域
本发明涉及药物、保健品或食品技术领域,尤其涉及一种缓解酒精性肝损伤的组合物及其制备工艺。
背景技术
随着人们生活节奏的加快、生活质量的提高以及膳食结构的改变,酒及酒制品在的消费量逐年升高。嗜酒、酒精依赖等引发的健康问题不容忽视。肝脏是人体最大的代谢解毒器官,酒精性肝损伤是由于酒精所致肝细胞功能受损的动态病理过程,随着其病理变化过程的加重,酒精性肝损伤可逐渐形成酒精性脂肪肝、酒精性肝炎、酒精性肝硬化,甚至肝细胞癌等酒精性肝病,进而导致较为严重的临床结局。
长期或者过量饮酒时,由于肝脏代谢解毒能力下降,代谢产物堆积而造成细胞毒性作用,形成肝损伤。酒精为水溶性,分子量较小,容易透过细胞膜进入细胞内。酒精的代谢产物乙醛可以损害肝内各种细胞器和酶的结构功能,①使肝细胞内线粒体中脂肪酸的β-氧化和氧化磷酸化受损,引起脂质过氧化反应,增加了血液和肝脏细胞中游离脂肪酸的含量。②抑制肝内谷胱甘肽合成,使超过氧化酶的抗氧化能力减弱,肝细胞内的氧自由基增加,诱导线粒体损害。③酒精可以特异性增加胆碱需要量,从而抑制磷脂合成脂蛋白,抑制脂肪从肝中排出,而形成脂肪肝。④酒精干扰铁的代谢,铁可以催化脂质过氧化作用,进而加重引起肝细胞损伤。
中国专利CN 102907548 A公开了一种含解酒保脑护肝组份的糖果,属糖果食品加工业的技术领域。含解酒保脑护肝组份的糖果是由清热解毒、发表解肌、解热生津、清肝明目、清利湿热的中草药葛根、蒲公英及葡萄糖、维生素C、维生素B族等组配而成,采用低聚糖、糖醇、甜菊苷等原料按常规糖果生产的工艺制备成无毒副作用、无热量、不龋齿的解酒保脑护肝糖果,能有效地消除酒后头痛发热、头晕眼花、智力衰退、行为失态等现象,能分解酒毒、保护大脑、保护脏腑、调理脾胃。该发明精选的中草药原料既是食品又是药品,无毒无副作用,采用无热能的糖果原料制成的糖果不肥胖、不龋齿,利于糖尿病、肥胖人士吃用,给爱喝酒的人士带来健康的福音。
中国专利CN 105494841 A公开了一种护肝糖果,由以下重量百分比的组分制成:木糖醇40-60份、麦芽糖醇30-50份、异麦芽酮糖醇8-17份、山梨醇8-17份、乳糖醇8-17份、食用明胶8-17份、莱菔子8-17份、雷瓦8-17份、龙骨1-3份、鹿茸1-3份、桂枝1-3份。该发明提供的一种糖果成本低、不含蔗糖和葡萄糖,其原料低廉,配伍科学,长期食用具有护肝的功效。现有技术中的护肝组合物大都以中药粉原料简单组合为主,具体活性成分不稳定,且目前大多数缓解肝损伤的组合物口感不佳,患者难以长期服用。
发明内容
有鉴于现有技术的上述缺陷,本发明所要解决的技术问题是提供一种缓解酒精性肝损伤的组合物及其制备工艺。
一种缓解酒精性肝损伤的组合物,主要包括如下组分:
枳椇子粉、葛根粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶、L-丙氨酸、L-谷氨酰胺、山梨糖醇、异麦芽酮糖醇、木糖醇、硬脂酸镁。
具体的,所述缓解酒精性肝损伤的组合物,主要包括如下组分:
枳椇子粉80~120重量份、葛根粉10~30重量份、姜黄粉10~30重量份、蒲公英粉10~30重量份、栀子粉2~8重量份、砂仁粉2~8重量份、金花茶2~8重量份、L-丙氨酸110~130重量份、L-谷氨酰胺150~170重量份、山梨糖醇140~150重量份、异麦芽酮糖醇40~45重量份、木糖醇140~160重量份、硬脂酸镁6~10重量份。
优选的,所述缓解酒精性肝损伤的组合物,主要包括如下组分:枳椇子粉100重量份、葛根粉20重量份、姜黄粉20重量份、蒲公英粉20重量份、栀子粉5重量份、砂仁粉5重量份、金花茶5重量份、L-丙氨酸120重量份、L-谷氨酰胺160重量份、山梨糖醇145重量份、异麦芽酮糖醇42重量份、木糖醇150重量份、硬脂酸镁8重量份。
枳椇子,枳椇子为鼠李科植物枳椇Hovenia dulcis Thunb的干燥成熟果实,别名拐枣、木蜜、树蜜等。枳椇子始载于《唐本草》,在《本草纲目》《雷公炮制论》《救荒本草》《医林纂要》等多部医药著作中均有收载,常用于治酒醉、烦热、口渴、呕吐、二便不利等症,泡酒服亦能舒筋络。枳椇子主要含生物碱类、黄酮类、皂苷类、有机酸类、糖类等成分,能有效减轻酒精诱导的氧化性肝损伤,显著降低丙氨酸和天冬氨酸转氨酶、碱性磷酸酶和甘油三酯的水平,起到解酒和保肝的作用,此外,它具有抗肿瘤、抗衰老、抗纤维化、抑制组胺释放、抑制中枢神经等多方面的作用。
葛根,葛为多年生草质藤本植物,其地下圆柱形块根入药后为葛根,我国葛属植物资源丰富,主要分布于河南、湖北、江苏和江西等地。目前市场上药用葛根来源主要有2种:(1)葛根,又称野葛,为豆科植物野葛的干燥根;(2)粉葛,为豆科植物甘葛藤的干燥根。葛根是我国最常见的中药之一,始载于我国汉代的《神农本草经》,具有悠久的药食两用历史,有“亚洲人参”的美誉。葛根味甘辛,性平,入脾胃经,具生津止渴、解表退热和升阳透疹的功效。
姜黄,姜黄为姜科姜黄属植物姜黄(Curcumalonga L.)的干燥根茎,原产于印度,现广泛种植于包括我国在内的热带和亚热带地区,是多年生草本植物,药食同源。姜黄粉是来自于成熟根茎中的芳香黄色粉末,常用作食品添加剂。《唐本草》中列为中品,记载其味辛,苦,温,归脾、肝经。有破血行气、通经止痛之功。主治胸胁刺痛,闭经,癥瘕,风湿肩臂疼痛,跌仆肿痛。
蒲公英,属于菊科蒲公英属,是多年生草本植物。蒲公英别名婆婆丁、白鼓丁、华花郎、黄花地丁、华花郎等。蒲公英具有非常高的中医药学价值,在我国古代《本草经疏》、《本草述》、《本草新编》、《本草图经》等中医药学著作中都有所记载。蒲公英味苦、甘,性寒,入肝胃两经,不但有清热解毒、利尿通淋、消肿散结、健胃消炎和保肝利胆的功效,还有清热活血的功能。现代研究表明,蒲公英中含有丰富生物活性物质,包括黄酮类物质、多糖、酚类化合物、甾醇、生物碱、萜类、糖蛋白、低聚糖等,具有抑菌、抗氧化、抗肿瘤、调节激素水平、降血糖血脂、保护肝脏和前列腺等功能。
栀子,为茜草科栀子属植物栀子的干燥果实,最早记载于《神农本草经》,《伤寒论》《闽东本草》《普济方》《圣济总录》等均有收载。栀子性味苦寒,具有泻火除烦、清热利湿、凉血解毒的功效,主治热病心烦、湿热黄疸、淋证涩痛、血热吐衄、目赤肿痛、火毒疮疡和外伤扭挫伤痛。
砂仁,是姜科植物阳春砂、绿壳砂或海南砂的干燥成熟果实。其性温,味辛,主归脾、胃、肾经。传统认为砂仁具有化湿开胃、温脾止泻和理气安胎的功效,在临床上主要用于湿浊中阻,脘痞不饥,脾胃虚寒,呕吐泄泻,妊娠恶阻,胎动不安等病症的治疗,且有较好的效果。
金花茶,为山茶科、山茶属常绿灌木或小乔木,在山花茶家族中具有唯一遗留下来的原始植物,分布范围小,全世界90%野生金花茶仅分布于中国广西防城港市十万大山的兰山支脉一带。金花茶药用具有清热解毒、利尿消肿的功效,用于咽喉炎、痢疾、肾炎、水肿、尿路感染、黄疸型肝炎、肝硬化腹水、高血压、疮疡、预防肿瘤。
本发明以枳椇子粉、葛根粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶等作为肝损伤组合物的主要功效成分,并在此基础上添加了L-丙氨酸和L-谷氨酰胺,以及辅料山梨糖醇、异麦芽酮糖醇、木糖醇、硬脂酸镁制备成压片糖果。中医的传统理论认为,酒毒具湿热二邪,发病迅猛,对脑、肝、脾胃、肾的损害较大,而本发明配方制备得到的压片糖果能减缓乙醇氧化成有毒物质乙醛,降低乙醛对身体的损害,具备清热解毒、清肝明目、调理肾脏及脾胃,加速酒毒的分解与排泻,缓解酒精性肝损伤的功能。但在上述压片糖果的制备过程中易发生潮解,且上述压片糖果中酚类物质含量较高,在制备过程以及贮藏过程中稳定性不够好,从而易导致其解酒护肝功效的下降。
有鉴于上述缺陷,本发明在所述缓解酒精性肝损伤的组合物中还添加了抗性淀粉粒。
更优选的,所述缓解酒精性肝损伤的组合物,包括如下组分:枳椇子粉80~120重量份、葛根粉10~30重量份、姜黄粉10~30重量份、蒲公英粉10~30重量份、栀子粉2~8重量份、砂仁粉2~8重量份、金花茶2~8重量份、L-丙氨酸110~130重量份、L-谷氨酰胺150~170重量份、山梨糖醇140~150重量份、异麦芽酮糖醇40~45重量份、木糖醇140~160重量份、硬脂酸镁6~10重量份、抗性淀粉粒10~30重量份。
具体的,所述抗性淀粉粒为青香蕉抗性纳米淀粉粒或β-胡萝卜素-青香蕉抗性纳米淀粉粒中的任意一种。
所述青香蕉抗性纳米淀粉粒采用如下方法制备得到:将1.5~2重量份青香蕉粉分散在20~30重量份0.1~0.2mol/L pH为4.5~5的乙酸-乙酸钠缓冲液中,搅拌后得到悬浮液,再将悬浮液在沸水浴中糊化30~50min,同时不断搅拌,再冷却至56~58℃后,再按照30~40U/g青香蕉粉的量添加支链淀粉酶,然后于56~58℃下酶解4~6h,酶解反应结束后,于沸水中加热10~15min终止酶解,冷却至20~25℃后于3500~4000rpm下离心5~8min去除多余的酶,然后以1~1.5mL/min的速度滴入50~80mL无水乙醇,用100~120W超声波分散5~10min得到混合物,最后将混合物以5000~7000rpm的转速离心5~10min,去除上清液取沉淀,用乙醇冲洗沉淀物2~3次后冷冻干燥得到所述青香蕉抗性纳米淀粉粒。
具体的,所述β-胡萝卜素-青香蕉抗性纳米淀粉粒的制备方法如下:
S1将1.5~2重量份青香蕉粉分散在20~30重量份0.1~0.2mol/L pH为4.5~5的乙酸-乙酸钠缓冲液中,搅拌后得到悬浮液,再将悬浮液在沸水浴中糊化30~50min,同时不断搅拌,再冷却至56~58℃后,再按照30~40U/g青香蕉粉的量添加支链淀粉酶,然后于56~58℃下酶解4~6h,酶解反应结束后,于沸水中加热10~15min终止酶解,冷却至20~25℃后于3500~4000rpm下离心5~8min去除多余的酶,然后以1~1.5mL/min的速度滴入50~80mL无水乙醇,用100~120W超声波分散5~10min得到混合物,最后将混合物以5000~7000rpm的转速离心5~10min,去除上清液取沉淀,用乙醇冲洗沉淀物2~3次后冷冻干燥得到所述青香蕉抗性纳米淀粉粒;
S2取20~30重量份β-胡萝卜素溶解在40~60重量份丙酮水溶液中,再向其中加入10~15重量份青香蕉抗性纳米淀粉粒,于65~70℃下搅拌20~30min,然后冷却至2~5℃后于2500~3000rpm下离心15~20min,除去上清,收集沉淀物,用蒸馏水冲洗2~3次,在40~45℃下干燥10~12h即得所述β-胡萝卜素-青香蕉抗性纳米淀粉粒。
本发明还提供了所述缓解酒精性肝损伤的组合物的制备方法,包括如下步骤:
A1检验;
A2过筛;
A3称量;
A4制粒;
A5干燥、整粒;
A6总混;
A7中间品水分测定;
A8压片;
A9内包装;
A10外包装;
A11检验、入库。
具体的,所述缓解酒精性肝损伤的组合物的制备方法,包括如下步骤:
A1检验:所有原辅料、内包装材料必须检验合格后才能领用进入生产;
A2过筛:将山梨糖醇过40目筛,如有结团物料过40~50目筛;
A3称量:按配方量准确称取各原辅料,备用;
A4制粒:将配方量的枳椇子粉、葛根粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶、异麦芽酮糖醇、L-谷氨酰胺、用92~95wt%乙醇溶液进行制粒,按浆粉质量比2~3%进行喷浆制粒,湿整粒目数16~20目;
A5干燥、整粒:将制好的颗粒烘干,干燥物料温度设定为55~60℃,干燥40~60min;
A6总混:将干燥好的颗粒置于混合机中,加入配方量的山梨糖醇、L-丙氨酸、木糖醇、抗性淀粉粒加入总混,混合20~30min,再添加硬脂酸镁混合5~8min至色泽均匀;
A7中间品水分测定:测中间品的水分含量,取水分含量≤5.0%的中间品;
A8压片:按800mg/片进行压片,片重差异±5%(760mg-840mg),片形要求完整光洁、色泽均匀,无松片、裂片、断片或其它异常情况;
A9内包装:按每瓶装60片进行装瓶,瓶中放入干燥剂,盖好盖子;
A10外包装:贴标签装彩盒;
A11检验、入库:产品经取样检验合格后,将已包装的成品入库。
本发明制备的缓解酒精性肝损伤的组合物添加了多种天然活性成分,能减缓乙醇氧化成有毒物质乙醛,降低乙醛对身体的损害,具备清热解毒、清肝明目、调理肾脏及脾胃,加速酒毒的分解与排泻,缓解酒精性肝损伤的功能。而本发明中添加的抗性淀粉粒能降低所述缓解酒精性肝损伤的组合物的持水力,能防止该组合物在制备及贮藏过程中的潮解,同时抗性淀粉粒中的β-胡萝卜素与青香蕉抗性纳米淀粉粒结合后形成了一种包体配合物,能与组合物中大量的酚类物质结合,有利于酚类物质的稳定,从而使得组合物具备更稳定的功效。
具体实施方式
结合一下具体实施例,对本发明作进一步的详细说明。实施发明的过程、条件、实验方法等,除以下专门提及的内容之外,均为本领域的普通知识和公知常识,本发明没有特别限制内容。
为免赘述,以下实施例中用到的药品若无特别说明则均市售产品,用到的方法若无特别说明则均为常规方法。
枳椇子粉,二氢杨梅素含量为30%,陕西斯诺特生物技术有限公司;
葛根粉,葛根黄酮含量为40%,陕西斯诺特生物技术有限公司;
姜黄粉,姜黄素含量≥10%,陕西斯诺特生物技术有限公司;
蒲公英粉,黄酮含量≥4%,陕西斯诺特生物技术有限公司。
实施例1
一种缓解酒精性肝损伤的组合物,包括以下组分:枳椇子粉100g、葛根粉20g、姜黄粉20g、蒲公英粉20g、栀子粉5g、砂仁粉5g、金花茶5g、L-丙氨酸120g重量份、L-谷氨酰胺160g、山梨糖醇145g、异麦芽酮糖醇42g、木糖醇150g、硬脂酸镁8g。
所述缓解酒精性肝损伤的组合物的制备方法,包括如下步骤:
A1检验:所有原辅料、内包装材料必须检验合格后才能领用进入生产;
A2过筛:将山梨糖醇过40目筛,如有结团物料过40目筛;
A3称量:按配方量准确称取各原辅料,备用;
A4制粒:将配方量的枳椇子粉、葛根粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶、异麦芽酮糖醇、L-谷氨酰胺、用95wt%乙醇溶液进行制粒,按浆粉质量比3%进行喷浆制粒,湿整粒目数20目;
A5干燥、整粒:将制好的颗粒烘干,干燥物料温度设定为60℃,干燥60min;
A6总混:将干燥好的颗粒置于混合机中,加入配方量的山梨糖醇、L-丙氨酸、木糖醇加入总混,混合20min,再添加硬脂酸镁混合5min至色泽均匀;
A7中间品水分测定:测中间品的水分含量,取水分含量≤5.0%的中间品;
A8压片:按800mg/片进行压片,片重差异±5%(760mg-840mg),片形要求完整光洁、色泽均匀,无松片、裂片、断片或其它异常情况;
A9内包装:按每瓶装60片进行装瓶,瓶中放入干燥剂,盖好盖子;
A10外包装:贴标签装彩盒;
A11检验、入库:产品经取样检验合格后,将已包装的成品入库。
所述成品符合GB 17399-2016。
实施例2
一种缓解酒精性肝损伤的组合物,包括以下组分:枳椇子粉100g、葛根粉20g、姜黄粉20g、蒲公英粉20g、栀子粉5g、砂仁粉5g、金花茶5g、L-丙氨酸120g重量份、L-谷氨酰胺160g、山梨糖醇145g、异麦芽酮糖醇42g、木糖醇150g、硬脂酸镁8g、抗性淀粉粒25g。
所述缓解酒精性肝损伤的组合物的制备,包括如下步骤:
A1检验:所有原辅料、内包装材料必须检验合格后才能领用进入生产;
A2过筛:将山梨糖醇过40目筛,如有结团物料过40目筛;
A3称量:按配方量准确称取各原辅料,备用;
A4制粒:将配方量的枳椇子粉、葛根粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶、异麦芽酮糖醇、L-谷氨酰胺、用95wt%乙醇溶液进行制粒,按浆粉质量比3%进行喷浆制粒,湿整粒目数20目;
A5干燥、整粒:将制好的颗粒烘干,干燥物料温度设定为60℃,干燥60min;
A6总混:将干燥好的颗粒置于混合机中,加入配方量的山梨糖醇、L-丙氨酸、木糖醇、抗性淀粉粒加入总混,混合20min,再添加硬脂酸镁混合5min至色泽均匀;
A7中间品水分测定:测中间品的水分含量,取水分含量≤5.0%的中间品;
A8压片:按800mg/片进行压片,片重差异±5%(760mg-840mg),片形要求完整光洁、色泽均匀,无松片、裂片、断片或其它异常情况;
A9内包装:按每瓶装60片进行装瓶,瓶中放入干燥剂,盖好盖子;
A10外包装:贴标签装彩盒;
A11检验、入库:产品经取样检验合格后,将已包装的成品入库。
所述抗性淀粉粒为青香蕉抗性纳米淀粉粒,采用如下方法制备得到:将20g青香蕉粉分散在300g 0.2mol/L pH为5的乙酸-乙酸钠缓冲液中,搅拌后得到悬浮液,再将悬浮液在沸水浴中糊化50min,同时不断搅拌,再冷却至58℃后,再按照40U/g青香蕉粉的量添加支链淀粉酶,然后于58℃下酶解6h,酶解反应结束后,于沸水中加热10min终止酶解,冷却至25℃后于4000rpm下离心5min去除多余的酶,然后以1mL/min的速度滴入50mL无水乙醇,用100W超声波分散5min得到混合物,最后将混合物以5000rpm的转速离心10min,去除上清液取沉淀,用乙醇冲洗沉淀物3次后冷冻干燥得到所述青香蕉抗性纳米淀粉粒。
所述成品符合GB 17399-2016。
实施例3
一种缓解酒精性肝损伤的组合物,包括以下组分:枳椇子粉100g、葛根粉20g、姜黄粉20g、蒲公英粉20g、栀子粉5g、砂仁粉5g、金花茶5g、L-丙氨酸120g重量份、L-谷氨酰胺160g、山梨糖醇145g、异麦芽酮糖醇42g、木糖醇150g、硬脂酸镁8g、抗性淀粉粒25g。
所述缓解酒精性肝损伤的组合物的制备,包括如下步骤:
A1检验:所有原辅料、内包装材料必须检验合格后才能领用进入生产;
A2过筛:将山梨糖醇过40目筛,如有结团物料过40目筛;
A3称量:按配方量准确称取各原辅料,备用;
A4制粒:将配方量的枳椇子粉、葛根粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶、异麦芽酮糖醇、L-谷氨酰胺、用95wt%乙醇溶液进行制粒,按浆粉质量比3%进行喷浆制粒,湿整粒目数20目;
A5干燥、整粒:将制好的颗粒烘干,干燥物料温度设定为60℃,干燥60min;
A6总混:将干燥好的颗粒置于混合机中,加入配方量的山梨糖醇、L-丙氨酸、木糖醇、抗性淀粉粒加入总混,混合20min,再添加硬脂酸镁混合5min至色泽均匀;
A7中间品水分测定:测中间品的水分含量,取水分含量≤5.0%的中间品;
A8压片:按800mg/片进行压片,片重差异±5%(760mg-840mg),片形要求完整光洁、色泽均匀,无松片、裂片、断片或其它异常情况;
A9内包装:按每瓶装60片进行装瓶,瓶中放入干燥剂,盖好盖子;
A10外包装:贴标签装彩盒;
A11检验、入库:产品经取样检验合格后,将已包装的成品入库。
所述抗性淀粉粒为β-胡萝卜素-青香蕉抗性纳米淀粉粒,采用如下方法制备得到:
S1将20g青香蕉粉分散在300g 0.2mol/L pH为5的乙酸-乙酸钠缓冲液中,搅拌后得到悬浮液,再将悬浮液在沸水浴中糊化50min,同时不断搅拌,再冷却至58℃后,再按照40U/g青香蕉粉的量添加支链淀粉酶,然后于58℃下酶解6h,酶解反应结束后,于沸水中加热10min终止酶解,冷却至25℃后于4000rpm下离心5min去除多余的酶,然后以1mL/min的速度滴入50mL无水乙醇,用100W超声波分散5min得到混合物,最后将混合物以5000rpm的转速离心10min,去除上清液取沉淀,用乙醇冲洗沉淀物3次后冷冻干燥得到所述青香蕉抗性纳米淀粉粒;
S2取20g β-胡萝卜素溶解在50g丙酮水溶液中,再向其中加入10g青香蕉抗性纳米淀粉粒,于70℃下搅拌20~30min,然后冷却至5℃后于3000rpm下离心20min,除去上清,收集沉淀物,用蒸馏水冲洗3次,在45℃下干燥12h即得所述β-胡萝卜素-青香蕉抗性纳米淀粉粒。
所述丙酮水溶液由丙酮和水按体积比2:1混合而成。
所述成品符合GB 17399-2016。
对照例1
一种缓解酒精性肝损伤的组合物,包括以下组分:葛根粉20g、姜黄粉20g、蒲公英粉20g、栀子粉5g、砂仁粉5g、金花茶5g、L-丙氨酸120g重量份、L-谷氨酰胺160g、山梨糖醇145g、异麦芽酮糖醇42g、木糖醇150g、硬脂酸镁8g。
所述缓解酒精性肝损伤的组合物的制备方法,包括如下步骤:
A1检验:所有原辅料、内包装材料必须检验合格后才能领用进入生产;
A2过筛:将山梨糖醇过40目筛,如有结团物料过40目筛;
A3称量:按配方量准确称取各原辅料,备用;
A4制粒:将配方量的葛根粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶、异麦芽酮糖醇、L-谷氨酰胺、用95wt%乙醇溶液进行制粒,按浆粉质量比3%进行喷浆制粒,湿整粒目数20目;
A5干燥、整粒:将制好的颗粒烘干,干燥物料温度设定为60℃,干燥60min;
A6总混:将干燥好的颗粒置于混合机中,加入配方量的山梨糖醇、L-丙氨酸、木糖醇加入总混,混合20min,再添加硬脂酸镁混合5min至色泽均匀;
A7中间品水分测定:测中间品的水分含量,取水分含量≤5.0%的中间品;
A8压片:按800mg/片进行压片,片重差异±5%(760mg-840mg),片形要求完整光洁、色泽均匀,无松片、裂片、断片或其它异常情况;
A9内包装:按每瓶装60片进行装瓶,瓶中放入干燥剂,盖好盖子;
A10外包装:贴标签装彩盒;
A11检验、入库:产品经取样检验合格后,将已包装的成品入库。
所述成品符合GB 17399-2016。
对照例2
一种缓解酒精性肝损伤的组合物,包括以下组分:枳椇子粉100g、姜黄粉20g、蒲公英粉20g、栀子粉5g、砂仁粉5g、金花茶5g、L-丙氨酸120g重量份、L-谷氨酰胺160g、山梨糖醇145g、异麦芽酮糖醇42g、木糖醇150g、硬脂酸镁8g。
所述缓解酒精性肝损伤的组合物的制备方法,包括如下步骤:
A1检验:所有原辅料、内包装材料必须检验合格后才能领用进入生产;
A2过筛:将山梨糖醇过40目筛,如有结团物料过40目筛;
A3称量:按配方量准确称取各原辅料,备用;
A4制粒:将配方量的枳椇子粉、姜黄粉、蒲公英粉、栀子粉、砂仁粉、金花茶、异麦芽酮糖醇、L-谷氨酰胺、用95wt%乙醇溶液进行制粒,按浆粉质量比3%进行喷浆制粒,湿整粒目数20目;
A5干燥、整粒:将制好的颗粒烘干,干燥物料温度设定为60℃,干燥60min;
A6总混:将干燥好的颗粒置于混合机中,加入配方量的山梨糖醇、L-丙氨酸、木糖醇加入总混,混合20min,再添加硬脂酸镁混合5min至色泽均匀;
A7中间品水分测定:测中间品的水分含量,取水分含量≤5.0%的中间品;
A8压片:按800mg/片进行压片,片重差异±5%(760mg-840mg),片形要求完整光洁、色泽均匀,无松片、裂片、断片或其它异常情况;
A9内包装:按每瓶装60片进行装瓶,瓶中放入干燥剂,盖好盖子;
A10外包装:贴标签装彩盒;
A11检验、入库:产品经取样检验合格后,将已包装的成品入库。
所述成品符合GB 17399-2016。
对照例3
一种缓解酒精性肝损伤的组合物,包括以下组分:枳椇子粉100g、葛根粉20g、姜黄粉20g、栀子粉5g、砂仁粉5g、金花茶5g、L-丙氨酸120g重量份、L-谷氨酰胺160g、山梨糖醇145g、异麦芽酮糖醇42g、木糖醇150g、硬脂酸镁8g。
所述缓解酒精性肝损伤的组合物的制备方法,包括如下步骤:
A1检验:所有原辅料、内包装材料必须检验合格后才能领用进入生产;
A2过筛:将山梨糖醇过40目筛,如有结团物料过40目筛;
A3称量:按配方量准确称取各原辅料,备用;
A4制粒:将配方量的枳椇子粉、葛根粉、姜黄粉、栀子粉、砂仁粉、金花茶、异麦芽酮糖醇、L-谷氨酰胺、用95wt%乙醇溶液进行制粒,按浆粉质量比3%进行喷浆制粒,湿整粒目数20目;
A5干燥、整粒:将制好的颗粒烘干,干燥物料温度设定为60℃,干燥60min;
A6总混:将干燥好的颗粒置于混合机中,加入配方量的山梨糖醇、L-丙氨酸、木糖醇加入总混,混合20min,再添加硬脂酸镁混合5min至色泽均匀;
A7中间品水分测定:测中间品的水分含量,取水分含量≤5.0%的中间品;
A8压片:按800mg/片进行压片,片重差异±5%(760mg-840mg),片形要求完整光洁、色泽均匀,无松片、裂片、断片或其它异常情况;
A9内包装:按每瓶装60片进行装瓶,瓶中放入干燥剂,盖好盖子;
A10外包装:贴标签装彩盒;
A11检验、入库:产品经取样检验合格后,将已包装的成品入库。
所述成品符合GB 17399-2016。
测试例1
缓解酒精性肝损伤功效测试:
试验动物:雄性Wister大鼠,SPF级,体重140±10g,由中国医学科学院试验动物研究所提供,许可证号:scxk11-00-0006。
将64只大鼠随机分成8组,正常对照组、醉酒模型组、实施例一组、实施例二组、实施例三组、对照例一组、对照例二组、对照例三组,每组8只。
将本发明中实施例及对照例获得的缓解酒精性肝损伤的组合物粉碎后给大鼠灌胃,灌胃量为1.6g/kg/d,正常对照组和醉酒模型组给予等量蒸馏水。
给药1h后按0.1mL/10g的饮酒量,给醉酒模型组、实施例一组、实施例二组、实施例三组、对照例一组、对照例二组、对照例三组的小鼠灌胃给予50°二锅头酒,正常对照组的大鼠灌胃给予等量蒸馏水。连续灌胃3天,每天一次,得到大鼠连续三天醉酒模型。
用全自动血液生化分析仪(SYSMEXCA-510)检测血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)的水平,具体测试结果如表1:
表1大鼠血液指标检测结果
组别 | ALT(U/L) | AST(U/L) | ALP(U/L) |
正常对照组 | 25.36±3.48 | 105.23±10.12 | 223.28±6.49 |
醉酒模型组 | 51.79±4.12 | 139.25±9.16 | 262.12±9.16 |
实施例一组 | 39.25±3.63 | 112.46±10.63 | 230.03±5.23 |
实施例二组 | 36.55±3.98 | 109.30±8.49 | 228.11±5.30 |
实施例三组 | 34.56±3.30 | 107.39±8.82 | 227.28±4.52 |
对照例一组 | 42.03±3.65 | 116.19±7.31 | 240.33±5.64 |
对照例二组 | 43.56±4.89 | 118.27±8.56 | 242.02±7.35 |
对照例三组 | 43.59±4.11 | 117.49±7.48 | 242.55±6.80 |
由表1可知,本发明制备得到的缓解酒精性肝损伤的组合物具备一定的解酒护肝功能,可能是由于本发明中添加的各种活性成分相互作用,能减缓乙醇氧化成有毒物质乙醛,降低乙醛对机体的损害,能加速酒毒的分解与排泻,缓解酒精性肝损伤。通过结果可知,本发明中采用枳椇子粉、葛根粉、蒲公英粉三者复配时效果相比添加其中任意一种时更佳,而添加了β-胡萝卜素-青香蕉抗性纳米淀粉粒的组合物具备最佳的护肝效果。
测试例2
稳定性测试:对实施例及对照例制备的缓解酒精性肝损伤的组合物进行抗氧化性的测定,测试方法如下:
将实施例1~3制备得到的缓解酒精性肝损伤的组合物成品在25℃下避光保存0、6个月后观察组合物的压片以及潮解情况;将实施例1~3制备得到的缓解酒精性肝损伤的组合物成品在25℃下避光保存0、30天后,再将组合物研磨配制成50mg/mL的水溶液后测定其DPPH自由基清除率:取3mL等体积的待测液与2×10﹣4mol/L的DPPH溶液混匀(A1管);取等体积的无水乙醇与2×10﹣4mol/L的DPPH溶液混匀(A2管);取等体积的无水乙醇与待测液混匀(A3管);30℃避光反应30min后,以蒸馏水为空白组,在517nm下测A1、A2、A3管的吸光度值,分别记作ODA1、ODA2和ODA3。DPPH自由基清除率根据如下公式进行计算,测试结果如表2:
表2稳定性测试结果表
由表2可知,实施例3中制备得到的缓解酒精性肝损伤的组合物成品具备最好的稳定性,实施例3中添加的抗性淀粉粒能降低所述缓解酒精性肝损伤的组合物的持水力,能防止该组合物在制备及贮藏过程中的潮解,同时抗性淀粉粒中的β-胡萝卜素与青香蕉抗性纳米淀粉粒结合后形成了一种包体配合物,能与组合物中大量的酚类物质结合,有利于酚类物质的稳定,保护了组合物的抗氧化性,也使得组合物具备更稳定的功效。
Claims (9)
1.一种缓解酒精性肝损伤的组合物,其特征在于,包括如下组分:枳椇子粉80~120重量份、葛根粉10~30重量份、姜黄粉10~30重量份、蒲公英粉10~30重量份、栀子粉2~8重量份、砂仁粉2~8重量份、金花茶2~8重量份、L-丙氨酸110~130重量份、L-谷氨酰胺150~170重量份、山梨糖醇140~150重量份、异麦芽酮糖醇40~45重量份、木糖醇140~160重量份、硬脂酸镁6~10重量份。
2.如权利要求1所述的缓解酒精性肝损伤的组合物,其特征在于,还包括抗性淀粉粒10~30重量份。
3.如权利要求2所述的缓解酒精性肝损伤的组合物,其特征在于:所述抗性淀粉粒为青香蕉抗性纳米淀粉粒或β-胡萝卜素-青香蕉抗性纳米淀粉粒中的任意一种。
4.如权利要求3所述的缓解酒精性肝损伤的组合物,其特征在于:所述青香蕉抗性纳米淀粉是将青香蕉粉用支链淀粉酶酶解后再滴入乙醇超声后沉淀得到。
5.如权利要求4所述的缓解酒精性肝损伤的组合物,其特征在于,所述青香蕉抗性纳米淀粉的制备方法为:将1.5~2重量份青香蕉粉分散在20~30重量份0.1~0.2mol/L pH为4.5~5的乙酸-乙酸钠缓冲液中,搅拌后得到悬浮液,再将悬浮液在沸水浴中糊化30~50min,冷却至56~58℃后,按照30~40U/g青香蕉粉的量添加支链淀粉酶,于56~58℃下酶解4~6h,再终止酶解,冷却后离心去除多余的酶,然后以1~1.5mL/min的速度滴入50~80mL无水乙醇,用100~120W超声波分散5~10min得到混合物,最后将混合物离心5~10min,去除上清液取沉淀,用乙醇冲洗沉淀物2~3次后冷冻干燥得到青香蕉抗性纳米淀粉粒。
6.如权利要求3所述的缓解酒精性肝损伤的组合物,其特征在于:所述β-胡萝卜素-青香蕉抗性纳米淀粉粒是将青香蕉抗性纳米淀粉粒与β-胡萝卜素在丙酮水溶液中进行结合得到。
7.如权利要求1~6任一项所述的缓解酒精性肝损伤的组合物的制备方法,其特征在于,包括如下步骤:
A1检验;
A2过筛;
A3称量;
A4制粒;
A5干燥、整粒;
A6总混;
A7中间品水分测定;
A8压片;
A9内包装;
A10外包装;
A11检验、入库。
8.如权利要求7所述的缓解酒精性肝损伤的组合物的制备方法,其特征在于:所述步骤A4制粒工艺按照浆粉质量比2~3%进行喷浆制粒,湿整粒目数为16~20目。
9.如权利要求7所述的缓解酒精性肝损伤的组合物的制备方法,其特征在于,所述步骤A5干燥物料温度设定为55~60℃,干燥时间为40~60min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210536391.3A CN114949139B (zh) | 2022-05-17 | 2022-05-17 | 一种缓解酒精性肝损伤的组合物及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210536391.3A CN114949139B (zh) | 2022-05-17 | 2022-05-17 | 一种缓解酒精性肝损伤的组合物及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114949139A true CN114949139A (zh) | 2022-08-30 |
CN114949139B CN114949139B (zh) | 2023-02-03 |
Family
ID=82982444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210536391.3A Active CN114949139B (zh) | 2022-05-17 | 2022-05-17 | 一种缓解酒精性肝损伤的组合物及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114949139B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102266057A (zh) * | 2011-08-22 | 2011-12-07 | 华南理工大学 | 具有润肠通便和减轻体重功能的香蕉粉的制作方法 |
CN102846771A (zh) * | 2012-07-04 | 2013-01-02 | 贵州省生物研究所 | 一种具有解酒保肝作用的组合物 |
CN104041896A (zh) * | 2014-06-10 | 2014-09-17 | 福州宸昌贸易有限公司 | 一种药食同源植物浓缩汁及其制备方法 |
CN104172159A (zh) * | 2014-07-24 | 2014-12-03 | 北京中泰天和科技有限公司 | 一种对酒精性肝损伤具有辅助保护作用的组合物及其制备方法 |
CN104784295A (zh) * | 2015-04-27 | 2015-07-22 | 无限极(中国)有限公司 | 一种解酒护肝中药组合物及其制备方法 |
CN110819669A (zh) * | 2019-12-02 | 2020-02-21 | 吉林大学珠海学院 | 一种香蕉抗性淀粉的制备方法 |
-
2022
- 2022-05-17 CN CN202210536391.3A patent/CN114949139B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102266057A (zh) * | 2011-08-22 | 2011-12-07 | 华南理工大学 | 具有润肠通便和减轻体重功能的香蕉粉的制作方法 |
CN102846771A (zh) * | 2012-07-04 | 2013-01-02 | 贵州省生物研究所 | 一种具有解酒保肝作用的组合物 |
CN104041896A (zh) * | 2014-06-10 | 2014-09-17 | 福州宸昌贸易有限公司 | 一种药食同源植物浓缩汁及其制备方法 |
CN104172159A (zh) * | 2014-07-24 | 2014-12-03 | 北京中泰天和科技有限公司 | 一种对酒精性肝损伤具有辅助保护作用的组合物及其制备方法 |
CN104784295A (zh) * | 2015-04-27 | 2015-07-22 | 无限极(中国)有限公司 | 一种解酒护肝中药组合物及其制备方法 |
CN110819669A (zh) * | 2019-12-02 | 2020-02-21 | 吉林大学珠海学院 | 一种香蕉抗性淀粉的制备方法 |
Non-Patent Citations (3)
Title |
---|
卞科等: "甘薯抗性淀粉的制备工艺及应用研究进展", 《河南工业大学学报(自然科学版)》 * |
张淑雅等: "护肝灵胶囊对酒精中毒大鼠和小鼠的保护作用", 《福建中医药》 * |
武小辉等: "小麦食品加工中低血糖指数配料的研究进展", 《食品工业科技》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114949139B (zh) | 2023-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109568538B (zh) | 包含水飞蓟、姜黄、甘草以及决明子的宿醉消解用组合物 | |
US6416795B1 (en) | Herbal extract composition for stress prevention and treatment | |
CN104982599A (zh) | 一种植物凉茶浓缩液及低糖植物凉茶饮料 | |
CN106135891A (zh) | 一种对酒精性肝损伤具有保护功能的保健食品 | |
CN102178885B (zh) | 一种用于醒酒的药物组合物 | |
CN102579958B (zh) | 解酒护肝组合物、提取物及其制备方法和制剂 | |
KR100771524B1 (ko) | 혼합 생약 추출물을 유효성분으로 함유하는 간 기능 개선용조성물 | |
CN110051815A (zh) | 一种辅助降血糖食丸及其制备方法 | |
KR100947278B1 (ko) | 하엽 추출물을 주성분으로 하는 탄수화물 및 지방 흡수억제 활성을 가지는 생약 조성물과 이의 제조 방법 | |
CA2574185A1 (en) | Body fat-reducing agent | |
CN110679708A (zh) | 一种具有护肝保健功能的药糖食品及其制备方法 | |
JP4516958B2 (ja) | 抗糖尿病用組成物 | |
CN114949139B (zh) | 一种缓解酒精性肝损伤的组合物及其制备工艺 | |
CN112439018A (zh) | 具有减肥降脂的组合物及其制备方法和应用 | |
CN107136245A (zh) | 一种纯草本减肥袋泡茶保健食品及其制备方法 | |
KR100543556B1 (ko) | 초두구 및 갈화를 함유하는 조성물 | |
CN115444922A (zh) | 一种抗疲劳药食同源组合物及其应用 | |
KR20090081062A (ko) | 당뇨병 예방 치료 및 내장 기능 치료제 조성물과 그 제조방법 | |
CA2667829A1 (en) | Ingestibles containing beneficial diabetic ingredient | |
CN114009795A (zh) | 一种保护肝脏的大鲵肽营养组合物 | |
KR101154031B1 (ko) | 혼합 생약재 추출물을 유효성분으로 함유하는 피로회복용 조성물 | |
CN110959721A (zh) | 一种食凉茶固体饮料 | |
CN110876717A (zh) | 一种可稳定血糖制品的制备方法 | |
CN105560733B (zh) | 一种保健酒 | |
CN117179112A (zh) | 一种解酒护肝和胃中药酵素软糖及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |